Liver biopsy remains the gold standard in the assessment of severity of liver disease. Noninvasive tests have gained popularity to predict histology in view of the associated risks of biopsy. However, many models include tests not readily available, and there are limited data from patients with HIV/
Expanding the applicability of noninvasive fibrosis markers in HIV/HCV co-infected patients
✍ Scribed by Leonardo L. Schiavon; Roberto J. Carvalho Filho; Janaína L. Narciso; Juliana P. Sampaio; Valéria P. Lanzoni; Maria Lucia G. Ferraz; Antonio Eduardo B. Silva
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 66 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
We read with interest the article by Sterling et al. 1 The authors derived from the AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT) 2 an index (FIB-4) to predict liver fibrosis in patients with HIV and hepatitis C virus (HCV) coinfection. The variables entered in the FIB-4 are as si
HCV infection is common among patients with end-stage renal disease (ESRD) on hemodialysis, and it has been considered an independent risk factor for mortality in this setting. Although liver biopsy in ESRD patients with HCV infection is useful before kidney transplantation, it carries a high risk o
## Abstract HCV replication in extra‐hepatic reservoirs has been suggested to occur in many tissues including PBMCs. A recent study showed evidence for compartmentalization and evolution of HCV in PBMCs. However, the cells that support HCV replication in PBMCs have not been identified. In this stud
Hepatits C (HCV) infection is frequent among hemophilic patients treated with non-inactivated factor-concentrates. Both HCV genotype and viral load have been suggested to be important prognostic markers of disease progression and treatment outcome. In addition, co-infection with the human immunodefi
Poynard owns stock in Biopredictive. He also consults for and is on the speakers' bureau of Merck. Dr. Pol consults for, advises, and is on the speakers' bureau of Boehringer Ingleheim, Abbott, and GlaxoSmithKline. He consults for, advises, is on the speakers' bureau of, and received grants from Roc